Find out what The Global Health Network can do for you. Register now.
This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
Marseille, France – ZIKAlliance, ZikaPLAN, ZIKAction, and ZIKAVAX – the four EU-funded consortia – participated and presented their research findings at the International Symposium on Zika Virus Research, held in Marseille, France, between 4 and 6 June 2018. Importantly, the four consortia discussed for the first time a common strategy for a ZIKV vaccine development thanks to inputs from ZIKAVAX. The aim of this project is to produce a safe, effective, and affordable preventive vaccine by using a delivery platform technology based on a measles vector (MV).
Other than Zika vaccine, the conference covered surveillance, burden estimates, modelling, clinical biology, vectors and vector control, cohort studies, lessons from imported cases, social and ethical implications of Zika, basic research and antivirals. In addition to well-established and senior scientists, around 30 young researchers had the opportunity to present their findings and scientific results. In total, 240 researchers took part in the three-day international symposium.
Meeting in-between the sessions of the conference, ZIKAlliance, ZikaPLAN, and ZIKAction updated each other on current and future collaborative efforts, such as the Joint Data Sharing Agreement (JDSA). The Agreement is a key tool for undertaking harmonized pregnant women and children cohort studies, and to study the risk of birth defects and developmental abnormalities related to Zika virus infections. As pointed out by Thomas Jaenisch, the JDSA “provides a framework for sharing data between the three EU-funded consortia. We concentrate on the key area of research in the pregnant women and children cohorts – the risk estimates of congenital abnormalities in infants and later abnormalities (such as developmental milestones) in children - and the risk of intrauterine infection in the first place (challenge for diagnostics).”
During the joint Executive Committee (ExCom) on June 5th, the three projects coordinators – Xavier de Lamballerie, Annelies Wilder-Smith, and Carlo Giaquinto – stressed the need to showcase some of the most important scientific results achieved by the three consortia. REDe, an online platform tasked with creating a regional research network focused on building research capacity by collecting high quality data, was also represented at the conference and internal meetings.
Finally, the ExCom was followed by the ZIKA-COLLAB meeting on June 6th, where members of the joint group discussed and worked on the upcoming cross-consortia newsletter.
Event supported by the European Union's Horizon 2020 Research and Innovation Programme under
ZIKAlliance Grant Agreement no. 734548 - ZikaPLAN Grant Agreement no. 734584
ZIKAction Grant Agreement no. 734857 - ZIKAVAX Grant Agreement no. 732432